Development of a two-component nanoparticle vaccine displaying an HIV-1 envelope glycoprotein that elicits Tier 2 neutralising antibodies
Despite treatment and other interventions, an effective prophylactic HIV vaccine is still an essential goal in the control of HIV. Inducing robust and long-lasting antibody responses is one of the main targets of an HIV vaccine. Delivery of HIV Env using nanoparticle (NP) vaccines has been shown to elicit better immunogenicity than soluble HIV Env.…